Fette Tablet Press Produces High Volumes - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Fette Tablet Press Produces High Volumes


Fette's FE75 Tablet Press, a double-sided rotary press, is designed for large batches and can be equipped with up to 115 punch stations to produce more than 1.6 million tablets per hour. The FE75’s four compression rollers feature a special control system for direct compression, enabling the machine to operate with two intermediate pressures.

The FE75 Tablet Press shares several technologies with the FE Series’ other two machines, the FE35 and FE55.  Common features include a patent-pending conical filling unit, highly accurate manually adjustable filling table, a revamped operating terminal, and the connection of process equipment through a standardized plug-and-play interface.  While the FE35 single-sided rotary press is optimized for quick changeovers and the FE55 offers maximum flexibility in diverse production scenarios, the FE75 has been specifically tailored to high-volume output for large batch production.

The FE75 has a footprint of only two square meters and is the only double-sided rotary press of its size that enables users to press single- and double-layer tablets as well as powder. Pneumatically controlled tablet scrapers guarantee a constant surface pressure and minimize product loss.  New conical filling units allow for the easier, safer processing of complex product mixtures, and tablet contamination is significantly hindered by a lubrication system that separates the lubrication of punch head and punch shaft in combination with a closed-cam track system. The FE75 chassis is designed with a two-part frame structure and a pneumatic suspension system for optimum vibration dampening.

The FE Series incorporates Fette Compacting’s TRI.EASY design concept of ease of use during production, changeover, and maintenance that is irrespective of an operator’s experience and qualifications. A new approach to turret changing, for example, uses a patent-pending process by which the turret is raised using a lifting mechanism. All steps involved in turret changeover have been automated or designed for tool-less execution. In addition, a new extraction unit features a tubeless design with fixed positioning to ensure correct installation.

Source: Fette

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race

Click here